Celcuity Inc. Sets Date for Q2 2024 Financial Results and Webcast

Celcuity Inc., a biotechnology firm based in Minneapolis, is advancing in the field of oncology with its focus on developing targeted therapies for solid tumors. The company, which trades on the Nasdaq under the ticker CELC, plans to disclose its financial results for the second quarter of 2024 after the market closes on August 14. On the same day, the company’s management will host a webcast and teleconference at 4:30 p.m. Eastern Time to discuss these results and provide a corporate update.

Celcuity’s primary therapeutic candidate is gedatolisib, a comprehensive inhibitor of both PI3K and mTOR enzymes. This candidate distinguishes itself from currently approved and investigational therapies by targeting both PI3K and mTOR pathways. The company is currently conducting several clinical trials to explore the effectiveness of gedatolisib in various cancer treatments.

One of the key trials is VIKTORIA-1, a Phase 3 study evaluating the combination of gedatolisib and fulvestrant, with or without the addition of palbociclib, for patients with HR+/HER2- advanced breast cancer. This trial is actively enrolling participants, and more information can be found on ClinicalTrials.gov.

Additionally, Celcuity is conducting a Phase 1b/2 trial, CELC-G-201, which examines the combination of gedatolisib and darolutamide in patients with metastatic castration-resistant prostate cancer.

Looking ahead, Celcuity plans to initiate VIKTORIA-2, another Phase 3 trial, in the second quarter of 2025. This study will assess the combination of gedatolisib, a CDK4/6 inhibitor, and fulvestrant as a first-line treatment for patients with HR+/HER2- advanced breast cancer.

Celcuity is committed to advancing its research and development in targeted oncology therapies, which may offer new treatment avenues for patients with various solid tumors.